Vaxart Announces the Publication of Studies in the Peer-Reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease SARS-CoV-2 TransmissionGlobeNewsWire • 05/19/22
These 3 Former High-Flying Stocks Can Soar Up to 439%, According to Wall StreetThe Motley Fool • 05/18/22
Vaxart Provides Business Update and Reports First Quarter 2022 Financial ResultsGlobeNewsWire • 05/09/22
3 COVID-19 Stocks With Monster Upside of Up to 355%, According to Wall StreetThe Motley Fool • 04/06/22
VAXART ALERT: Bragar Eagel & Squire, P.C. is Investigating Vaxart, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 03/30/22
Vaxart: A Speculative Biotech With Potential As Covid-19 Play And Oral Vaccine PlatformSeeking Alpha • 02/26/22
Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewsWire • 02/24/22
Vaxart's S-Only COVID-19 Vaccine Candidate Produces Strong-Cross Reactive Mucosal and Systemic Immune Responses in Non-Human PrimatesGlobeNewsWire • 02/24/22
Earnings Preview: VAXART, INC. (VXRT) Q4 Earnings Expected to DeclineZacks Investment Research • 02/17/22
All You Need to Know About VAXART, INC. (VXRT) Rating Upgrade to BuyZacks Investment Research • 02/07/22